Clinically, the ACE I/D polymorphism seems to influence the therapeutic outcome in patients with depression, including the onset of action of antidepressant pharmacotherapies and the responses to selective serotonin reuptake inhibitors (SSRIs) (70), which plays an important role in the individualized treatment of depression. This evidence concerns the gene ACE and depressive symptom measurement.